Differential immunogenicity of two peptides isolated by high molecular weight-melanoma-associated antigen-specific monoclonal antibodies with different affinities.
Peptide mimics isolated from phage display peptide libraries by panning with self-tumor-associated Ag (TAA)-specific mAbs are being evaluated as immunogens to implement active specific immunotherapy. Although TAA-specific mAb are commonly used to isolate peptide mimics, no information is available regarding the Ab characteristics required to isolate immunogenic TAA peptide mimics. To address this question, we have used mAb 763.74 and mAb GH786, which recognize the same or spatially close antigenic determinant(s) of the human high m.w.-melanoma-associated Ag (HMW-MAA), although with different affinity. mAb 763.74 affinity is higher than that of mAb GH786. Panning of phage display peptide libraries with mAb 763.74 and mAb GH786 resulted in the isolation of peptides P763.74 and PGH786, respectively. When compared for their ability to induce HMW-MAA-specific immune responses in BALB/c mice, HMW-MAA-specific Ab titers were significantly higher in mice immunized with P763.74 than in those immunized with PGH786. The HMW-MAA-specific Ab titers were markedly increased by a booster with HMW-MAA-bearing melanoma cells, an effect that was significantly higher in mice primed with P763.74 than in those primed with PGH786. Lastly, P763.74, but not PGH786, induced a delayed-type hypersensitivity response to HMW-MAA-bearing melanoma cells. These findings suggest that affinity for TAA is a variable to take into account when selecting mAb to isolate peptide mimics from a phage display peptide library.
Luo
Wei
W
Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Hsu
Jeff Chi-feng
JC
Tsao
Chun-yen
CY
Ko
Eric
E
Wang
Xinhui
X
Ferrone
Soldano
S
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology; D019264:Adoptive Transfer; D000818:Animals; D000912:Antibodies, Neoplasm / Q000378:metabolism*; D000951:Antigens, Neoplasm / Q000008:administration & dosage / Q000276:immunology* / Q000378:metabolism*; D001666:Binding Sites, Antibody; D045744:Cell Line, Tumor; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007117:Immunization, Secondary; D017912:Inovirus / Q000235:genetics; D008545:Melanoma / Q000276:immunology* / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D018716:Molecular Mimicry / Q000276:immunology; D008970:Molecular Weight; D010446:Peptide Fragments / Q000008:administration & dosage / Q000138:chemical synthesis / Q000276:immunology* / Q000378:metabolism*; D019151:Peptide Library; D000099216:Chondroitin Sulfate Proteoglycan 4
D000276:Adjuvants, Immunologic; D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D010446:Peptide Fragments; D019151:Peptide Library; D000099216:Chondroitin Sulfate Proteoglycan 4